SELECTED IMPORTANT SAFETY INFORMATION ABOUT KOGENATE FS, KOVALTRY, AND JIVI 
KOGENATE FS, KOVALTRY, and JIVI are contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins. JIVI is also contraindicated in patients who have a history of hypersensitivity reactions to polyethylene glycol (PEG). ...Continue reading below

Kovaltry®: An unmodified, full length recombinant Factor VIII treatment with a cell bank derived from the Kogenate® FS cell line11

Information for adolescent and adult patients.

Explore data below on Kogenate FS patients who transitioned to Kovaltry as part of a clinical trial.

Kovaltry Prophylaxis Treatment

    LEOPOLD I Clinical Trial (n=62)

    Study Design
    The multinational, open-label prospective study of previously treated patients aged 12-65 years with severe hemophilia A evaluated efficacy and safety of Kovaltry 2x/week (n=18) or 3x/week (n=44) prophylaxis. The primary efficacy endpoint was annualized bleed rate (ABR) at 12 months.2

    1 Median
    ABR

    (n=62)
    (IQR=0.0; 5.1)12

    Median dose:
    31.2 IU/kg
    (range: 21-43 IU/kg)12

    0 inhibitors

    in 62 previously treated patients2

    People with hemophilia A may develop inhibitors to rFVIII.2*

    The most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), and pyrexia, headache and rash.

    Post-hoc subgroup analysis (n=22)

    22 adolescent and adult Kogenate FS patients transitioned to Kovaltry prophylaxis as part of the LEOPOLD I clinical trial.9

    Kogenate FS patients experienced fewer annual bleeds after transitioning to Kovaltry9†

    Kogenate FS ABR prior to study enrollment*

    2.5

    Median ABR

    (n=22)
    (IQR=0.0; 9.0)9

    Kovaltry ABR during study

    1
    Median
    ABR

    (n=22)
    (IQR=0.0; 6.8)9

    Median dose:
    35.4 IU/kg
    (range: 23.99-49.26)9

    0 inhibitors

    in the subgroup analysis of 22 previously treated patients9

    People with hemophilia A may develop inhibitors to rFVIII.9‡

    There were no drug-related adverse events in this subgroup during the 12 months of the main trial.

    Kovaltry offers adult and adolescent Kogenate FS patients the opportunity to stay on the same dose and frequency1,2.

        Kogenate FS  Kovaltry   
    Dose  
      25 IU/kg  
    20 IU/kg   40 IU/kg Potential to stay on the same dose

    Frequency  
    3x per week  
    3x per week 2x per week
    Potential to stay on the same infusion frequency or reduce frequency
    Kogenate FS Kovaltry 
    Dose
     
    25 IU/kg

    Potential to stay on the same dose

    20 IU/kg  40 IU/kg

    Frequency
    3x per week

    Potential to stay on the same infusion frequency or reduce frequency

    3x per week
    2x per week

    Kovaltry offers prophylaxis patients currently on Kogenate FS…

    • The potential to stay on the same dose and frequency2
    • A cell bank derived from the Kogenate FS cell line11
    • Advancements to the Kogenate manufacturing process, including2:
      • Removal of human and animal derived raw materials from the cell culture
      • Addition of 20nm filtration step

    In a post hoc subgroup analysis, Kogenate FS patients who transitioned to Kovaltry prophylaxis as part of clinical trial experienced8-10:

    • A reduction in ABR*
    • Zero inhibitors
    • The most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), and pyrexia, headache, and rash.

    Kovaltry On-Demand Treatment

      LEOPOLD II Clinical Trial (N=21)

      The safety and efficacy of Kovaltry for on-demand treatment in adolescent and adult (12 to 65 years of age) previously treated patients (PTPs) was evaluated for 12 months2,15

      kovaltry adults - tab 3 circle - eficacy draw

      Circular chart.

      95.2%
      of bleeds were treated
      with ≤2 infusions15

      21.6% of total bleeds were trauma bleeds.15

      75.5%
      1 infusion15

      19.7%
      2 infusions15

      4.8%
      3+ infusions15

      21.6% of total bleeds were trauma bleeds.15

      0 inhibitors
      in the main study analysis of 21 previously treated patients.15

      One patient in the on-demand group (n=21) experienced a mild drug-related adverse event (infusion site pruritus).15

      Subgroup analysis (n=10)

      10 Kogenate FS on-demand patients transitioned to Kovaltry on-demand as part of the clinical trial.15

      kovaltry adults - tab 4 - circle eficacy transitioned draw

      Circular chart.

      96.7%
      of bleeds were treated
      with ≤2 infusions15

      15.9% of total bleeds were trauma bleeds.15

      85.9%
      1 infusion15

      10.8%
      2 infusions15

      3.3%
      3+ infusions15

      15.9% of total bleeds were trauma bleeds.15

      0 inhibitors
      in the subgroup analysis of 10 previously treated patients.15

      There were no drug-related adverse events in the subgroup.16

      Kovaltry offers on-demand patients currently on Kogenate FS…

      • A cell bank derived from the Kogenate FS cell line11
      • Advancements to the Kogenate manufacturing process, including2:
        • Removal of human and animal derived raw materials from the cell culture
        • Addition of 20nm filtration step

      In a post hoc subgroup analysis, Kogenate FS patients who transitioned to Kovaltry on-demand as part of a clinical trial experienced15:

      • 96.7% of bleeds treated with ≤2 infusions
      • Zero inhibitors
      • There were no drug-related adverse events in this subgroup.16

      For more information on Kovaltry, visit the Kovaltry website.

      Click here to go to the Resources page where you can download this information.

      ISI v2 - Important Safety Information v3

      Indications and Important Safety Information

      Indication For KOGENATE® FS

      KOGENATE FS is an Antihemophilic Factor (Recombinant) indicated for:

      • On-demand treatment and control of bleeding episodes in adults and children with hemophilia A.
      • Perioperative management of bleeding in adults and children with hemophilia A.
      • Routine prophylaxis to reduce the frequency of bleeding episodes in children with hemophilia A and to reduce the risk of joint damage in children without pre-existing joint damage.
      • Routine prophylaxis to reduce the frequency of bleeding episodes in adults with hemophilia A.

      Indication For KOVALTRY®

      KOVALTRY Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

      • On-demand treatment and control of bleeding episodes
      • Perioperative management of bleeding
      • Routine prophylaxis to reduce the frequency of bleeding episodes

      Indication For JIVI®

      JIVI antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:

      • On-demand treatment and control of bleeding episodes
      • Perioperative management of bleeding
      • Routine prophylaxis to reduce the frequency of bleeding episodes

      Limitations of Use For JIVI:

      • JIVI is not indicated for use in children
        less than 12 years of age due to a greater risk for hypersensitivity reactions.
      • JIVI is not indicated for use in previously untreated patients (PUPs).

      KOGENATE FS, KOVALTRY, and JIVI are not indicated for the treatment of von Willebrand disease.

      Important Safety Information About KOGENATE FS, KOVALTRY, and JIVI

      • KOGENATE FS, KOVALTRY, and JIVI are contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins. JIVI is also contraindicated in patients who have a history of hypersensitivity reactions to polyethylene glycol (PEG).
      • Hypersensitivity reactions, including severe allergic reactions, are possible with KOGENATE FS, KOVALTRY, and JIVI. Monitor patients for hypersensitivity symptoms. 
        Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOGENATE
        FS, KOVALTRY, or JIVI if symptoms occur and seek immediate emergency treatment.
      • KOGENATE FS, KOVALTRY, and JIVI may contain trace amounts of mouse and hamster proteins. Patients treated with KOGENATE FS, KOVALTRY, or JIVI may develop hypersensitivity to these non-human mammalian proteins.
      • Neutralizing antibodies (inhibitors) have occurred following administration of KOGENATE FS, KOVALTRY, and JIVI predominately in previously untreated patients. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, suspect the presence of an inhibitor.
      • For JIVI, a clinical immune response associated with IgM anti-PEG antibodies, manifested as symptoms of acute hypersensitivity and/or loss of drug effect, has been observed primarily in patients < 6 years of age. The symptoms of the clinical immune response were transient. Anti-PEG IgM titers decreased over time to undetectable levels. No immunoglobulin class switching was observed. In case of clinical suspicion of loss of drug effect, conduct testing for Factor VIII inhibitors and Factor VIII recovery.
      • For JIVI, a low post-infusion Factor VIII level in the absence of detectable Factor VIII inhibitors indicates that loss of drug effect is likely due to anti-PEG antibodies. Discontinue JIVI and switch patients to a previously effective Factor VIII product.
      • Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.
      • Catheter-related infections may occur when KOVALTRY is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

      In clinical trials with:

      • KOGENATE FS – the most common adverse reactions (≥4%) observed were inhibitor formation in previously untreated and minimally treated patients, skin-related hypersensitivity reactions, infusion site reactions, and CVAD-associated infections.
      • KOVALTRY – the most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), and pyrexia, headache, and rash.
      • JIVI – the most frequently (≥5%) reported adverse reactions in previously treated patients (PTPs) ≥12 years of age were headache, cough, nausea, and fever.

      For additional important risk and use information, please see the full Prescribing Information for KOGENATE FS, KOVALTRY, and JIVI.